NCT00002198已完成1 期
A Study to Investigate Whether There is a Pharmacokinetic Interaction Between 1592U89 and Ethanol Following Their Co-Administration to HIV-Infected Subjects.
Glaxo Wellcome2 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to see how the body processes 1592U89 and ethanol (pure grain alcohol) when they are given together.
详细描述
Patients are randomized to one of the following three regimens:
Regimen 1: 1592U89 alone. Regimen 2: pure grain alcohol diluted in orange juice. Regimen 3: 1592U89 plus pure grain alcohol diluted in orange juice. Treatment is administered weekly for 3 weeks.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Local treatment for Kaposi's sarcoma.
- •Prophylactic treatment for opportunistic infections.
- •Patients must have:
- •HIV-1 infection.
- •CD4+ lymphocyte count >= 200 cells/microliter within 14 days prior to study drug administration.
- •No active diagnosis of AIDS (other than visceral Kaposi's sarcoma) according to the 1993 Centers for Disease Control and Prevention (CDC) AIDS surveillance definition.
- •Prior Medication:
- •Local treatment for Kaposi's sarcoma.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms and conditions are excluded:
- •Malabsorption syndrome or other GI dysfunction which may interfere with drug absorption.
- •Concurrent Medication:
- •Medications that cannot be withheld for 48 hours (24 hours for antiretrovirals) prior to study drug administration and until 12 hours after study drug administration on each dosing day.
- •Immunomodulators, such as systemic corticosteroids, interleukins and interferons.
- •Cytotoxic chemotherapeutic agents.
- •Acute treatment for opportunistic infections.
- •Concurrent Treatment:
- •Radiation therapy.
- •Patients with the following prior conditions are excluded:
- •Documented history of alcoholism.
- •History of clinically relevant hepatitis or pancreatitis within 6 months prior to study drug administration.
- •History of hypersensitivity, anaphylactic, or idiosyncratic reaction to nucleoside analogs.
- •Participation in another research study within the past month.
- •Prior Medication:
- •Cytotoxic chemotherapeutic agents within six weeks prior to study drug administration.
- •Immunomodulating agents within six weeks prior to study drug administration.
- •Treatment with the following within 2 weeks prior to study drug administration:
- •acyclovir, carbamazepine, chloramphenicol, ganciclovir, phenytoin, rifampin, sodium valproate, or valacyclovir.
- •Prior Treatment:
- •Radiation therapy within 6 weeks prior to study drug administration.
- •1. Regular weekly alcohol intake of more than 21 units (a unit is equal to 1/2 pint beer or 1 glass of wine or 1 oz of liquor).
- •Recent change in normal pattern of alcohol usage (e.g., prolonged use followed by > one month abstinence).
- •Total abstinence from alcohol use.
- •Positive breath alcohol test upon arrival at the study center prior to any dosing day.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study)Potential Treatment for Alcohol Dependence-Alcohol InteractionNCT04331288Pop Test Oncology LLC10
已完成
1 期
EtOH Interaction StudySubstance DependenceNCT00887367GlaxoSmithKline20
招募中
不适用
Phosphatidylethanol and Other Ethanol Consumption MarkersHealthy VolunteerAlcohol ConsumptionNCT06747364The University of Texas Health Science Center at San Antonio80
招募中
不适用
Alcohol After Bariatric Surgery 2Sleeve GastrectomyNCT06257771University of Illinois at Urbana-Champaign88
已完成
不适用
Validation in Humans of Genes Involved in Alcohol Drinking, Stress-Induced Alcohol Drinking and RelapseAlcohol DrinkingNCT00326742Central Institute of Mental Health, Mannheim281